Toni K. Choueiri

The Immune Landscape of Cancer

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Post-acute COVID-19 syndrome

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Systemic Therapy for Metastatic Renal-Cell Carcinoma